
Hai L. Nguyen
Examiner (ID: 3, Phone: (571)272-1747 , Office: P/2842 )
| Most Active Art Unit | 2842 |
| Art Unit(s) | 2842, 2816 |
| Total Applications | 2273 |
| Issued Applications | 2006 |
| Pending Applications | 70 |
| Abandoned Applications | 222 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18762872
[patent_doc_number] => 11813251
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Methods of treating gastrointestinal stromal tumors
[patent_app_type] => utility
[patent_app_number] => 18/091743
[patent_app_country] => US
[patent_app_date] => 2022-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 54
[patent_no_of_words] => 17178
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18091743
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/091743 | Methods of treating gastrointestinal stromal tumors | Dec 29, 2022 | Issued |
Array
(
[id] => 18350300
[patent_doc_number] => 20230138411
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => PYRIMIDINE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 18/091790
[patent_app_country] => US
[patent_app_date] => 2022-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12331
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18091790
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/091790 | PYRIMIDINE COMPOUND | Dec 29, 2022 | Abandoned |
Array
(
[id] => 18349892
[patent_doc_number] => 20230138003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => DIHYDROINDOLIZINONE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 18/088045
[patent_app_country] => US
[patent_app_date] => 2022-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14714
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18088045
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/088045 | DIHYDROINDOLIZINONE DERIVATIVE | Dec 22, 2022 | Abandoned |
Array
(
[id] => 20432519
[patent_doc_number] => 12502388
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-23
[patent_title] => Lanthionine synthetase C-like 2-based therapeutics
[patent_app_type] => utility
[patent_app_number] => 18/085018
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 42
[patent_no_of_words] => 23619
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 215
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085018
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/085018 | Lanthionine synthetase C-like 2-based therapeutics | Dec 19, 2022 | Issued |
Array
(
[id] => 18590216
[patent_doc_number] => 11739096
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer
[patent_app_type] => utility
[patent_app_number] => 18/078087
[patent_app_country] => US
[patent_app_date] => 2022-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26307
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18078087
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/078087 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | Dec 7, 2022 | Issued |
Array
(
[id] => 19121010
[patent_doc_number] => 11964980
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
[patent_app_type] => utility
[patent_app_number] => 18/077466
[patent_app_country] => US
[patent_app_date] => 2022-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 40339
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077466
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/077466 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | Dec 7, 2022 | Issued |
Array
(
[id] => 20187025
[patent_doc_number] => 12398130
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-26
[patent_title] => Acid addition salts of piperazine derivatives
[patent_app_type] => utility
[patent_app_number] => 18/062295
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 32033
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 332
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062295
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062295 | Acid addition salts of piperazine derivatives | Dec 5, 2022 | Issued |
Array
(
[id] => 18418479
[patent_doc_number] => 20230172937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/061467
[patent_app_country] => US
[patent_app_date] => 2022-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -104
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061467
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/061467 | TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASES | Dec 3, 2022 | Pending |
Array
(
[id] => 18829593
[patent_doc_number] => 20230398117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives
[patent_app_type] => utility
[patent_app_number] => 18/060796
[patent_app_country] => US
[patent_app_date] => 2022-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34703
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060796
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060796 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | Nov 30, 2022 | Abandoned |
Array
(
[id] => 19042283
[patent_doc_number] => 11931356
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-03-19
[patent_title] => Compositions and methods for treating human papilloma virus infections
[patent_app_type] => utility
[patent_app_number] => 18/060391
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 25
[patent_no_of_words] => 5303
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060391
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060391 | Compositions and methods for treating human papilloma virus infections | Nov 29, 2022 | Issued |
Array
(
[id] => 18649313
[patent_doc_number] => 20230295101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => THERAPEUTIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/070993
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11181
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 292
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18070993
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/070993 | Therapeutic compounds | Nov 28, 2022 | Issued |
Array
(
[id] => 20621605
[patent_doc_number] => 12589099
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-31
[patent_title] => Alpha-1062 for treating traumatic brain injury
[patent_app_type] => utility
[patent_app_number] => 18/549309
[patent_app_country] => US
[patent_app_date] => 2022-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 18
[patent_no_of_words] => 23247
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549309
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/549309 | Alpha-1062 for treating traumatic brain injury | Nov 24, 2022 | Issued |
Array
(
[id] => 18347063
[patent_doc_number] => 20230135173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/049000
[patent_app_country] => US
[patent_app_date] => 2022-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17262
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -82
[patent_words_short_claim] => 322
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049000
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/049000 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Oct 23, 2022 | Abandoned |
Array
(
[id] => 18468764
[patent_doc_number] => 20230203046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/045770
[patent_app_country] => US
[patent_app_date] => 2022-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045770
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045770 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | Oct 10, 2022 | Issued |
Array
(
[id] => 18405755
[patent_doc_number] => 20230167106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/938502
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938502
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938502 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | Oct 5, 2022 | Abandoned |
Array
(
[id] => 18497321
[patent_doc_number] => 20230219938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => COMPOUNDS AND THEIR METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/959799
[patent_app_country] => US
[patent_app_date] => 2022-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17959799
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/959799 | COMPOUNDS AND THEIR METHODS OF USE | Oct 3, 2022 | Abandoned |
Array
(
[id] => 18739521
[patent_doc_number] => 20230348460
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/956435
[patent_app_country] => US
[patent_app_date] => 2022-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17956435
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/956435 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | Sep 28, 2022 | Issued |
Array
(
[id] => 18391346
[patent_doc_number] => 20230159564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers
[patent_app_type] => utility
[patent_app_number] => 17/949595
[patent_app_country] => US
[patent_app_date] => 2022-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 251
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17949595
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/949595 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | Sep 20, 2022 | Pending |
Array
(
[id] => 18801303
[patent_doc_number] => 11834454
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Alkynylphenylbenzamide compounds and applications thereof
[patent_app_type] => utility
[patent_app_number] => 17/948236
[patent_app_country] => US
[patent_app_date] => 2022-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 11495
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 230
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948236
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/948236 | Alkynylphenylbenzamide compounds and applications thereof | Sep 19, 2022 | Issued |
Array
(
[id] => 18147663
[patent_doc_number] => 20230021520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
[patent_app_type] => utility
[patent_app_number] => 17/949188
[patent_app_country] => US
[patent_app_date] => 2022-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17949188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/949188 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | Sep 19, 2022 | Pending |